title: Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.
abstract: Tumor necrosis factor alpha (TNFalpha) has broad effects on the immune system including lymphoid organ development as well as growth, survival und function of immune cells. TNFalpha has two main functions: regulatory effects and proinflammatory activities. In several diseases such as juvenile and adult "rheumatoid" arthritis, psoriasis and chronic inflammatory bowel disease, the application of TNFalpha-blocking medications has been beneficial. However, induction of inflammation in several organs including the eye, CNS, skin and gastrointestinal tract has been reported. We report on an 11-year-old girl with juvenile idiopathic arthritis, who developed Crohn's disease (CD) while taking etanercept for her arthritis. Etanercept was discontinued and an antibody-based anti-TNF treatment using adalimumab was started, which induced remission of the gastrointestinal symptoms promptly. This case indicates that immunodysregulatory and even proinflammatory effects of etanercept are of relevance in the clinical practice. Furthermore, TNFalpha as a part of its function seems to downregulate mucosal inflammation in CD.
authors.affiliation: Pediatric Rheumatology, Immunology, Gastroenterology and Infectious Diseases, Children's Hospital, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany. Wiegering_V@kinderklinik.uni-wuerzburg.de
authors.forename: V
authors.initials: V
authors.lastname: Wiegering
authors.forename: H
authors.initials: H
authors.lastname: Morbach
authors.forename: A
authors.initials: A
authors.lastname: Dick
authors.forename: H J
authors.initials: HJ
authors.lastname: Girschick
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D003424:Crohn Disease / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D000068800:Etanercept; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007049:Iatrogenic Disease; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007422:Intestines / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; D000068879:Adalimumab; D000068800:Etanercept